Xenetic Biosciences, Inc. (XBIO) — Financial statements
Income statement, balance sheet, and cash flow for Xenetic Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3↑19.0% | 3↓1.6% | 3↑48.8% | 2↑47.1% | 1 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 3↑19.0% | 3↓1.6% | 3↑48.8% | 2↑47.1% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓6.8% | 3↓5.9% | 3↓26.7% | 5↑50.8% | 3 | |
| General & Administrative Expenses | 3↓19.6% | 3↓4.1% | 4↓2.5% | 4↓2.4% | 4 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↓19.6% | 3↓4.1% | 4↓2.5% | 4↓2.4% | 4 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 6↓13.3% | 7↓5.0% | 7↓16.3% | 8↑22.0% | 7 | |
| Total Costs & Expenses | 6↓13.3% | 7↓5.0% | 7↓16.3% | 8↑22.0% | 7 | |
| Operating Results | ||||||
| Operating Income | -3↑32.6% | -4↑6.9% | -5↑32.8% | -7↓16.9% | -6 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.15 | 0.00↓100.0% | 0.03↓23.8% | 0.04 | |
| EBITDA | -3↑30.0% | -4↑10.3% | -5↑32.5% | -7↓17.2% | -6 | |
| EBIT | -3↑32.6% | -4↑6.9% | -5↑32.8% | -7↓16.9% | -6 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.15↓40.8% | 0.25↓29.8% | 0.36↑112.8% | 0.17↑66.4% | 0.10 | |
| Interest Income | 0.15↓40.8% | 0.25↓29.8% | 0.36↑112.8% | 0.17↑66.4% | 0.10 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.15↓37.0% | 0.24↓35.9% | 0.38↑130.2% | 0.17↑63.0% | 0.10 | |
| Income Before Tax | -3↑32.3% | -4↑4.2% | -4↑36.9% | -7↓16.1% | -6 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -3↑32.3% | -4↑4.2% | -4↑36.9% | -7↓16.1% | -6 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -3↑32.3% | -4↑4.2% | -4↑36.9% | -7↓16.1% | -6 | |
| Bottom-Line Net Income | -3↑32.3% | -4↑4.2% | -4↑36.9% | -7↓16.1% | -6 | |
| EPS (Basic) | -1.58↑38.5% | -2.57↑5.2% | -2.71↑39.6% | -4.49↑16.7% | -5.39 | |
| EPS (Diluted) | -1.58↑38.5% | -2.57↑5.2% | -2.71↑39.6% | -4.49↑16.7% | -5.39 | |
| Weighted Average Shares | 2↑10.4% | 2↑0.9% | 2↑7.4% | 1↑38.4% | 1 | |
| Weighted Average Diluted Shares | 2↑10.4% | 2↑0.9% | 2↑7.4% | 1↑38.4% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.